We recently sponsored the @BreakthroughT1D Walk in Chicago. Thank you to everyone who came out to raise funds and awareness for the local T1D community! See our team in action below, and learn more about our work in T1D on our trial website: bit.ly/3Qod3OK

Members of our team will be at the inaugural @BreakthroughT1D Clinical & Research Congress to discuss the trial for CNP-103, our investigational tolerizing therapy, with members of the type 1 diabetes community. Learn more about CNP-103 and our trial: bit.ly/3Qod3OK

Our CMO Paul Peloso, MD, and Trial Liaison Emily Hong, PharmD, RPh, will be at the 2026 @AANEMorg Annual Meeting to discuss the Phase 1b/2a trial for CNP-106, our investigational therapy for myasthenia gravis. Learn more about CNP-106 on our website: bit.ly/3Wty9Lo

September is Primary Biliary Cholangitis (PBC) Awareness Month. PBC is a chronic, progressive autoimmune liver disease that affects the daily lives of thousands of people, predominantly women. We stand with the PBC community. bit.ly/4xBw3t4

For our most recent #COURCares event, our team gathered for a @BlessinBackpack packing event. Together, they worked to make a difference in our community as they packed bags that will help feed 250 kids in Gary, Indiana. Check out the photos below to see our team in action!

Today we launch #MindsBehindCOUR, a series to recognize different members of our team. First up: Jade Zhao, Controller. She helps build the systems, controls, and financial discipline that support COUR long after any one milestone. Thank you, Jade!

We partnered with @GingerVieira of @diabetesnerd on a new article and video that highlight our trial enrolling people with recently diagnosed type 1 diabetes. Check out the links below! 🎥 bit.ly/45MVAE8 📖 bit.ly/4xVbtEj 👀 bit.ly/3Qod3OK

For a new Cell & Gene feature, Editor-in-Chief Erin Harris sat down with our Chief Scientific Officer, Adam Elhofy, PhD, to discuss our nanoparticle approach to treating autoimmune diseases via antigen-specific immune tolerance. Read the full article: bit.ly/45rSO73

Behind every trial is a team that makes it possible. Today we spotlight Texas Diabetes and Endocrinology in Austin. They are a site for our trial evaluating CNP-103, a potential treatment for recently diagnosed type 1 diabetes. Learn more: bit.ly/3Qod3OK

A day away from the lab to give back. 🌱🐦 As part of #COURCares, our community service initiative, we spent a day restoring native habitat at the Clark Street Beach Bird Sanctuary. See our team in action! For more on our culture, visit our website: bit.ly/45PGU8v

For us, working on a new approach to treating type 1 diabetes (T1D) is personal. In this video, family members of our COUR community discuss how they live with T1D. Our team also offers insights on our investigational therapy CNP-103. Watch more: bit.ly/40ptZqa

We enjoyed the recent Friends for Life Conference hosted by @cwdiabetes in Orlando. Thanks to everyone who visited our booth to learn about the science behind our work in type 1 diabetes. Check out the photos below, and visit our trial website for more: bit.ly/3Qod3OK

Our CEO, Dannielle Appelhans, and CSO, Adam Elhofy, PhD, took part in panels at #BIO2026. They joined peers from the industry to discuss pipeline strategy and developing new immune tolerance approaches to treating autoimmune diseases. Check out some photos from the panels below!

At #BIO2026, our CEO, Dannielle Appelhans, joined @BiotechTV to discuss how our nanoparticle platform works to reprogram the immune system and why we are advancing our lead program in type 1 diabetes. Watch the conversation via the link in the below post.

We’re pleased to share news of our Series B funding to support the advancement of CNP-103 currently in Phase 2 for T1D. This milestone brings us one step closer to our goal of changing what's possible for people living with this condition. Learn more: bit.ly/4eOTWqC

What’s next for biotech innovation and immune tolerance? Join us at #BIO2026, where Dannielle Appelhans, CEO, and Adam Elhofy, CSO, will share insights on building transformative pipelines & new approaches for autoimmune disease treatment. Learn more: bit.ly/3Wty9Lo

In June, we join @MyastheniaOrg in recognizing #MGAwarenessMonth. We aim to help increase awareness for the myasthenia gravis community and reinforce the importance of continued research into autoimmune diseases and the underlying drivers of immune dysfunction. Learn more below.

At #FOCIS2026, we will present research that highlights our antigen-specific immune tolerance platform in autoimmune diseases, including clinical data from our trial in primary biliary cholangitis (PBC). Details in the graphic below. Visit our website: bit.ly/3OcleNn

Later this week, members of our team will present on our antigen-specific immune tolerance approach to #Type1Diabetes at the #ADASciSessions. See the graphic below for details, and learn more about our #T1D program by visiting our website: bit.ly/3Wty9Lo

On #ClinicalTrialsDay, we thank the patients, families, and healthcare professionals advancing research in type 1 diabetes (T1D). Without you, trials like ours could not move forward. Visit our new site for info about our trial: bit.ly/3Qod3OK